Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.

International journal of molecular medicine - 1 Jul 2009

Zou Zu-Quan, Zhang Xiao-Hong, Wang Feng, Shen Qi-Jun, Xu Jin, Zhang Li-Na, Xing Wen-Hua, Zhuo Ren-Jie, Li Duo

Abstract excerpt

PI-103, the first synthetic multitargeted compound which simultaneously inhibits PI3Kalpha and mammalian target of rapamycin (mTOR) shows high antitumor activity in glioma xenografts. In the present study, clear antitumor activity was observed with PI-103 treatment in two gefitinib-resistant non-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Furans
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Pyridines

Share to Pyrimidines

Share to Quinazolines

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 19513541
DOI: 10.3892/ijmm_00000212

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19513541-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.PMID 19513541Read ↗

Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.Semantic proximity Read ↗

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.Semantic proximity Read ↗

New phosphatidylinositol 3-kinase inhibitors for cancer.Semantic proximity Read ↗

BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancerSemantic proximity Read ↗

WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.Semantic proximity Read ↗

A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma TherapySemantic proximity Read ↗

A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition.Semantic proximity Read ↗

The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.Semantic proximity Read ↗

Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.Semantic proximity Read ↗

[Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy].Semantic proximity Read ↗

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.Semantic proximity Read ↗

Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.